Alkem Laboratories Limited (ALKEM): research summary
Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Alkem Laboratories Limited, explained in plain English.
- Alkem Laboratories Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
- ALKEM closed at ₹5,222.50 on 18 November 2026.
- Over the past year the shares are down 8.6%, trading between ₹4,811.00 and ₹5,933.50.
- Reported fundamentals show return on equity of 14.19%, a net margin of 13.23%, debt to equity of 14.72.
- Our Pulse grade checklist scores it D (41/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
- Annualised volatility over the past year is 22.5% with a maximum drawdown of -16.01% and a beta of 0.67 against NIFTY 50.
- Recent coverage: Alkem Lab Q2 profit falls 14.4% to ₹667 cr; revenue rises to ₹4,552 cr
- Recent coverage: Alkem Laboratories Q2 Results: Net Profit Falls 12% To Rs 675 Crore; Ropes In Gopal Kothari As CFO
Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma, Biocon
Last traded values from 18 Nov 2026. Market opens at 9:15 IST.
Pharma & Healthcare · Drug Manufacturers - Specialty & Generic
Alkem Laboratories Limited (ALKEM)
₹5,222.5
▲ 47.5 (+0.92%)Price & volume
Hover for exact price & volume · green/red volume bars show up vs down days
Momentum check
Neutral momentum · 2/51M
+3.42%
3M
-4.61%
6M
-4.49%
1Y
-8.59%
Where it sits in its 52-week range
29%Below 52-week high
11.3%
5.6% above the low
Momentum read
Neutral
2/5 checks passed
52-wk high
₹5,890
52-wk low
₹4,947
Market cap
₹62,443 Cr
P/E (trailing)
30.2
Dividend yield
—
ROE
14.19%
Profit margin
13.23%
Revenue growth
13.8%
Price / Book
4.2
Debt / Equity
14.72
EPS (TTM)
172.93
Book value
₹1243.21
Beta
0.67
Pulse grade: D, 41 out of 100
Momentum
C- ✓Trading above 50-day average
- ✕Trading above 200-day average
- ✓RSI in healthy 45-70 zone
- ✕Positive 3-month return
Growth
F- ✕Revenue growth above Pharma & Healthcare median (20.8%)
- ✓Revenue growing above 5%
- ✕Quarterly profits trending up
Profitability
F- ✕Return on equity above Pharma & Healthcare median (14.56%)
- ✓Return on equity above 12%
- ✕Profit margin above Pharma & Healthcare median (13.82%)
Safety
A- ✓Debt below Pharma & Healthcare median (18.57)
- ✓Debt not extreme for the sector
- ✓Less volatile than the market (beta < 1.2)
- ✕Pays a dividend
Quarterly revenue vs net profit
Sep 2026: revenue ₹4,552 crore · net profit ₹675 crore · margin 14.8%
Business quality
Intrinsic value
Analyst coverage
Who owns this company
Events, dividends & splits
Market position
Pharma & Healthcare sector
ALKEM headlines
No ALKEM stories right now.
ALKEM filings & announcements
ALKEM, historical timeline
The timeline will be ready shortly
The rest of the page is unaffected.
Risk & return, last 12 months
Volatility (ann.)
22.5%
Sharpe ratio
-0.57
Sortino ratio
-0.76
Max drawdown
-16.01%
Daily VaR (95%)
-1.88%
CAGR (1Y)
-8.62%
Return skew
-0.65
Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.
Risk profile over time
Performance at a glance
Quant tearsheet
Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.